Near fatal anaphylaxis from orally administered gelatin capsule.
Duke University School of Medicine, Durham, NC. Electronic address: michael.h.land@kp.org.
Michael H
MH
Land
Mark D
MD
Piehl
A Wesley
AW
Burks
D000284:Administration, Oral; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000707:Anaphylaxis / Q000139:chemically induced* / Q000188:drug therapy; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D002214:Capsules; D002648:Child; D004155:Diphenhydramine / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005780:Gelatin / Q000008:administration & dosage / Q000009:adverse effects*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002214:Capsules; D006635:Histamine H2 Antagonists; D015738:Famotidine; D004155:Diphenhydramine; D005780:Gelatin; D011241:Prednisone; D007052:Ibuprofen; D004837:Epinephrine